Business Wire

BEARINGPOINT

17.5.2022 08:57:12 CEST | Business Wire | Press release

Share
BearingPoint Study: Does Your Data Underpin Resilience or Undermine It?

Management and technology consultancy BearingPoint has created a deep dive study on enterprise data resilience . This paper is the first of five companion pieces to the 2021 ‘Can you thrive under pressure’ study, the analysis of over 5,000 projects leading to the ranking of 150 best practice resilient organizations. BearingPoint has also created a resilience benchmarking tool that enables any organization to assess their own alignment with the five fundamental pillars of resilience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220516005860/en/

BearingPoint believe data and analytic resilience is undermined by lack of people empowerment, as 65% of organizations lack data literacy and 56% face cultural resistance to change. Other obstacles impacting data led change initiatives included lack of resources and funding (33%) and disconnect with the business strategy (20%). BearingPoint’s study also concludes that implementation is not easy. The study has found that organizations need a structured vision combined with a disciplined approach e.g., an effective data strategy: without it organizations will fail to generate benefits from investment.

BearingPoint’s research indicates that organizations’ data strategy can only be successful if it is underpinned by the five dimensions of a resilient organization:

1. Understand your data ecosystem: You need the right datapoints to take the right decisions

2. Empower your people for change: Make sure your people interact positively in the data value chain

3. Align data centricity with business outcomes: Steer your data journey so it is agile and focused on business outcomes

4. Use technology to improve agility: Select the architecture that will best support your business model

5. Build proper and effective governance: Data-centricity needs to involve your entire organization, not just leadership

Jan Henderyckx, Partner at BearingPoint asks “is data a hobby or holy grail in your organization? We are witnessing the start of a new industrial revolution, fuelled by data rather than coal. But we believe effective data-centric transformation is not about size, but attitude. Our research shows companies will only survive and thrive if they adopt a rounded, well-balanced and progressive approach across these five dimensions. All are vital. Only by delivering on all of them, your organization will become resilient to change. As all firms, in all sectors must understand that data needs to be at the heart of their business strategy.”

All categories of organization type that BearingPoint studied had room for improvement in the area of data resilience with organizations of all types showing maturing or developing data centricity. BearingPoint observed that Government organizations have lower data resilience scores than privately held and publicly listed companies. According to the study, a reason for this may be that privately held companies may have more scope to execute fast decision making (governance).

Jan Henderyckx will be discussing the study’s finding as the Plenary Keynote speaker at: Creating Data Centric Business Resilience at IRMUK Data Governance Conference Europe, May 18, 2022, in London.

“We are living in a world in which it is increasingly more important to be able to adapt to the changing environment. Your decisions should be based on facts rather than assumptions. Companies that put data centricity at the core of their strategy are going to create value. Especially if they apply a comprehensive approach to all dimensions that impact the implementation of a data strategy,’’ says Jan Henderyckx.

About the study

BearingPoint analyzed over 5,000 client projects, built a model to assess how organizations create successful long-term transformations, and then calibrated resilience profiles based on five observed characteristics. You can download the study here to find out more: https://www.bearingpoint.com/en-gb/insights-events/insights/data-must-be-at-the-heart-of-your-business-strategy/

About BearingPoint

BearingPoint is an independent management and technology consultancy with European roots and a global reach. BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.

www.bearingpoint.com
www.linkedin.com/company/bearingpoint
@BearingPoint

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye